The U.S. Food and Drug Administration (FDA) has approved Yartemlea (narsoplimab‑wuug), marking the first authorized therapy for hematopoietic stem cell transplant‑associated thrombotic microangiopathy (TA‑TMA) in adults and children aged 2…
As reported on PharmaBiz, AstraZeneca’s phase III LATIFY trial has fallen short of its primary objective, with the combination of the ATR inhibitor ceralasertib and the PD‑L1 inhibitor Imfinzi (durvalumab)…
As reported on FierceBioTech, Biohaven closed out the holiday period with disappointing news: its investigational Kv7.2/7.3 potassium‑channel modulator, BHV‑7000, did not demonstrate efficacy in a phase 2 clinical trial for…
Soleno Therapeutics has achieved a significant milestone in the treatment of a rare genetic disorder, announcing the publication of pivotal clinical study results for VYKAT™ XR in the prestigious Journal…
Altimmune has released updated 48-week results from its phase 2 trial of pemvidutide, a GLP-1/glucagon dual receptor agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), demonstrating continued weight loss and…
Coya Therapeutics has achieved an important regulatory milestone with U.S. FDA acceptance of an Investigational New Drug (IND) application for COYA 302, marking the advancement of a promising new treatment…
A new oral medication has demonstrated remarkable effectiveness in treating hereditary angioedema (HAE) attacks, offering patients significantly faster symptom relief compared to existing options. According to Healio.com, the RAPIDe-3 study…
As reported on PharmaBiz, Renalys Pharma has reported encouraging topline data from its Phase III trial evaluating sparsentan (RE-021), an oral dual endothelin and angiotensin II receptor antagonist, in Japanese…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
